BioCentury | Feb 25, 2013
Company News

Pantarhei, Actavis deal

...of cash and stock. Pantarhei is also eligible for milestones. The JV was formed by Pantarhei...
...Phase III development of the human fetal estrogen and plans to launch Estelle in 2018. Pantarhei...
...women with breast cancer and endometriosis. Estetrol is in Phase II testing for the indications. Pantarhei Bioscience B.V....
BioCentury | Jun 25, 2012
Clinical News

Pantarhei preclinical data

...to dose-dependent, significant reductions in the number and growth of tumors vs. vehicle-treated controls (p<0.01). Pantarhei...
...osteoporosis. Data were published in the Journal of Hormone and Molecular Biology and Clinical Investigation. Pantarhei Bioscience B.V....
BioCentury | Jul 19, 2010
Clinical News

Pill-Plus: Phase II data

...Data were presented at the European Society of Contraception meeting in The Hague, the Netherlands. Pantarhei...
...Pill-Plus for oral use in the U.S. from BioSante. BioSante Pharmaceuticals Inc. (NASDAQ:BPAX), Lincolnshire, Ill. Pantarhei Bioscience B.V....
BioCentury | Sep 15, 2008
Clinical News

Pill-Plus: Phase II data

...testosterone levels to the normal range of 1.3 to 8.0 pg/mL for premenopausal healthy women. Pantarhei...
...develop and commercialize Pill-Plus in the U.S. from BioSante. BioSante Pharmaceuticals Inc. (NASDAQ:BPAX), Lincolnshire, Ill. Pantarhei Bioscience B.V....
BioCentury | Jun 25, 2007
Clinical News

Oral contraceptive: Phase II started

...rights to the agent to Pantarhei earlier this year. BioSante Pharmaceuticals Inc. (BPA), Lincolnshire, Ill. Pantarhei Bioscience B.V....
Items per page:
1 - 5 of 5
BioCentury | Feb 25, 2013
Company News

Pantarhei, Actavis deal

...of cash and stock. Pantarhei is also eligible for milestones. The JV was formed by Pantarhei...
...Phase III development of the human fetal estrogen and plans to launch Estelle in 2018. Pantarhei...
...women with breast cancer and endometriosis. Estetrol is in Phase II testing for the indications. Pantarhei Bioscience B.V....
BioCentury | Jun 25, 2012
Clinical News

Pantarhei preclinical data

...to dose-dependent, significant reductions in the number and growth of tumors vs. vehicle-treated controls (p<0.01). Pantarhei...
...osteoporosis. Data were published in the Journal of Hormone and Molecular Biology and Clinical Investigation. Pantarhei Bioscience B.V....
BioCentury | Jul 19, 2010
Clinical News

Pill-Plus: Phase II data

...Data were presented at the European Society of Contraception meeting in The Hague, the Netherlands. Pantarhei...
...Pill-Plus for oral use in the U.S. from BioSante. BioSante Pharmaceuticals Inc. (NASDAQ:BPAX), Lincolnshire, Ill. Pantarhei Bioscience B.V....
BioCentury | Sep 15, 2008
Clinical News

Pill-Plus: Phase II data

...testosterone levels to the normal range of 1.3 to 8.0 pg/mL for premenopausal healthy women. Pantarhei...
...develop and commercialize Pill-Plus in the U.S. from BioSante. BioSante Pharmaceuticals Inc. (NASDAQ:BPAX), Lincolnshire, Ill. Pantarhei Bioscience B.V....
BioCentury | Jun 25, 2007
Clinical News

Oral contraceptive: Phase II started

...rights to the agent to Pantarhei earlier this year. BioSante Pharmaceuticals Inc. (BPA), Lincolnshire, Ill. Pantarhei Bioscience B.V....
Items per page:
1 - 5 of 5